German funds want tight drug budgets

22 January 2001

The leading German health funds have called for the strict maintenanceof doctors' pharmaceutical spending budgets and have rejected demands by the medical profession for an easing or lifting of budget restrictions. The funds say that the health service's financial problems are due to the uncontrolled increase in doctors, whose numbers went up 27% in 1999.

The funds welcome the government's intention of reaching a new health policy consensus with the doctors and funds in the new parliamentary period, but say the talks must recognize that retention of budgetary control in all areas of the health service is vital if health insurance contributions are to remain stable.

The funds also say there is a savings potential in the drug sector of at least 3 billion Deutschemarks ($1.45 billion), and that budget maintenance is not only vital but achievable. Budget overshoots have been avoided in over half the panel doctor associations, the funds say, and they urge the medical professions to continue in discussions over drug budgets with the government.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight